Showing 9781-9790 of 19172 results for "".
- Navigating Mental Health Challenges in Incarcerated Youth: Insights and Innovationshttps://reachmd.com/news/navigating-mental-health-challenges-in-incarcerated-youth-insights-and-innovations/2476128/Incarcerated youth are navigating unprecedented mental health challenges and demanding strategic reforms to ensure fair and effective psychological care, especially as ongoing insights into adolescent brain development reshape our approach to risk assessment and intervention. As high
- Breaking New Ground in Sjögren’s Disease: The Success of Ianalumab Phase III Trialshttps://reachmd.com/news/breaking-new-ground-in-sjogrens-disease-the-success-of-ianalumab-phase-iii-trials/2476129/Recent developments, exemplified by the promising Phase III results of ianalumab, may signal a shift in the treatment landscape for Sjögren’s disease, although detailed peer‑reviewed data and regulatory review are still pending. In this context, symptoms like dry mouth and eyes stem
- The Evolution of Surgical Techniques in Endometrial Cancer: From Laparotomy to Innovationhttps://reachmd.com/news/the-evolution-of-surgical-techniques-in-endometrial-cancer-from-laparotomy-to-innovation/2476095/As surgical techniques for endometrial cancer continue reshaping oncologic practice, the move from open laparotomy toward minimally invasive surgery is forging a new era of precision and patient-centered care. Building on decades of open surgery, a landmark
- Molecular Interventions for Treatment-Resistant Nephrotic Syndrome Focus on cdc42https://reachmd.com/news/molecular-interventions-for-treatment-resistant-nephrotic-syndrome-focus-on-cdc42/2476083/Amid rising rates of treatment-resistant nephrotic syndrome, relentless proteinuria demands novel interventions—molecular targets like cdc42 now command attention for their potential to reshape therapy. Nephrologists often grapple with patients whose proteinuria persists despite maxi
- Frontline Immunity: Universal Vaccine Development Against Evolving Pathogenshttps://reachmd.com/news/frontline-immunity-universal-vaccine-development-against-evolving-pathogens/2476085/Frontline clinicians and infectious disease specialists face an onslaught of antigenically drifting viruses and novel zoonoses that outpace pathogen-specific defenses; universal vaccine development and integrated antiviral measures promise the broad-spectrum immunity needed to stay ahead of
- Innovative Approaches to Combat Antibiotic Resistance: Phage Therapy and Long-Acting Antibioticshttps://reachmd.com/news/innovative-approaches-to-combat-antibiotic-resistance-phage-therapy-and-long-acting-antibiotics/2476091/A paradigm shift is under way as clinicians explore how bacteriophages—viruses that specifically infect bacteria—can evolve alongside resistant pathogens, potentially outpacing the arms race of antibiotic resistance; however, phage therapy remains investigational and is primarily administer
- Innovative Strategies Against Immune Evasion in HNSCChttps://reachmd.com/news/innovative-strategies-against-immune-evasion-in-hnscc/2476078/The battle against cancer often feels like a never-ending struggle, especially as tumor cells develop cunning strategies to evade the immune system. In head and neck squamous cell carcinoma (HNSCC), immune evasion presents a significant challenge to treatment efficacy, demanding inn
- Alzheimer's 2025: Embracing Immunomodulatory Microglia Strategieshttps://reachmd.com/news/alzheimers-2025-embracing-immunomodulatory-microglia-strategies/2476076/The 2025 Alzheimer's Consortium guidelines now emphasize immunomodulatory strategies targeting microglial activation, marking a departure from solely amyloid-centric approaches. As the brain’s resident immune sentinels, microglia orchestrate inflammatory cascades and amyloid clearanc
- Integrating GLP-1 Receptor Agonists in Comprehensive Obesity Managementhttps://reachmd.com/news/integrating-glp-1-receptor-agonists-in-comprehensive-obesity-management/2476071/GLP-1 receptor agonists enhance weight loss through multiple pathways. Agents such as liraglutide and semaglutide improve glycemic control, delay gastric emptying, and suppress appetite. A
- JAK Inhibitors in Dermatology: Transforming Autoimmune Pathwayshttps://reachmd.com/news/jak-inhibitors-in-dermatology-transforming-autoimmune-pathways/2476079/In dermatology, JAK inhibitors are rapidly emerging as potent agents in managing autoimmune conditions refractory to conventional therapies. By targeting the JAK-STAT pathway, these drugs offer a novel mechanism for modulating immune responses in granulomatous and other autoimmune skin dise